Literature DB >> 11248788

Trousseau's syndrome treated with long-term subcutaneous lepirudin (case report and review of the literature).

A C Andreescu1, M Cushman, J M Hammond, M E Wood.   

Abstract

We report here a case of recurrent venous and arterial thromboembolism, Trousseau's syndrome, in a cancer patient who developed heparin-induced thrombocytopenia. She was treated with lepirudin and after establishing the patient-specific half-life for subcutaneous lepirudin, she was successfully maintained on this therapy for more than eight months. To our knowledge this case represents the longest reported use of subcutaneous lepirudin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11248788     DOI: 10.1023/a:1008952126124

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  22 in total

1.  Evaluation of a pharmacy-based surveillance program for heparin-induced thrombocytopenia.

Authors:  A C Andreescu; C Possidente; M Hsieh; M Cushman
Journal:  Pharmacotherapy       Date:  2000-08       Impact factor: 4.705

2.  Migratory thrombophlebitis associated with ovarian carcinoma.

Authors:  W S WOMACK; C J CASTELLANO
Journal:  Am J Obstet Gynecol       Date:  1952-02       Impact factor: 8.661

Review 3.  College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban.

Authors:  M Laposata; D Green; E M Van Cott; T W Barrowcliffe; S H Goodnight; R C Sosolik
Journal:  Arch Pathol Lab Med       Date:  1998-09       Impact factor: 5.534

4.  A recombinant hirudin (IK-HIR02) in healthy volunteers. II. Effects on platelet adhesion and platelet-induced thrombin generation time.

Authors:  J F Schenk; E Glusa; P Radziwon; A Butti; F Markwardt; H K Breddin
Journal:  Haemostasis       Date:  1996 Jul-Aug

5.  Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study Group.

Authors:  F Schiele; F Lindgaerde; H Eriksson; J P Bassand; A Wallmark; P O Hansson; G Grollier; M Sjo; M Moia; A Camez; V Smyth; M Walker
Journal:  Thromb Haemost       Date:  1997-05       Impact factor: 5.249

6.  Trousseau's syndrome.

Authors:  N Callander; S I Rapaport
Journal:  West J Med       Date:  1993-04

Review 7.  The development of hirudin as an antithrombotic drug.

Authors:  F Markwardt
Journal:  Thromb Res       Date:  1994-04-01       Impact factor: 3.944

Review 8.  Heparin-induced thrombocytopenia: a ten-year retrospective.

Authors:  T E Warkentin
Journal:  Annu Rev Med       Date:  1999       Impact factor: 13.739

9.  Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin.

Authors:  X Song; G Huhle; L Wang; U Hoffmann; J Harenberg
Journal:  Circulation       Date:  1999-10-05       Impact factor: 29.690

10.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.

Authors:  T E Warkentin; M N Levine; J Hirsh; P Horsewood; R S Roberts; M Gent; J G Kelton
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

View more
  2 in total

Review 1.  Right atrial thrombus treated successfully with abciximab and heparin.

Authors:  A C Borges; R K Reibis; M Claus; G Baumann
Journal:  J Thromb Thrombolysis       Date:  2001-12       Impact factor: 2.300

2.  Outpatient management of venous thromboembolic disease with subcutaneous lepirudin: a case report.

Authors:  Susan M Begelman; Steven R Deitcher
Journal:  J Thromb Thrombolysis       Date:  2002-06       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.